Agusti, Alvar, Barnes, Neil, Cruz, Alvaro A., Gibson, Peter G., Heaney, Liam G., Inoue, Hiromasa, Leather, David, Martinez, Fernando J., McDonald, Vanessa M., Oppenheimer, John, Papi, Alberto, Pavord, Ian D., Thomas, Mike, Walker, Samantha and Yates, Louisa
(2021)
Moving towards a Treatable Traits model of care for the management of obstructive airways diseases.
Respiratory Medicine, 187, [106572].
(doi:10.1016/j.rmed.2021.106572).
More information
Accepted/In Press date: 6 August 2021
Published date: 13 August 2021
Additional Information:
Funding Information:
AP reports grants, personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, Chiesi, Edmondpharma, Fondazione Maugeri, GlaxoSmithKline, Menarini, Mundipharma, Novartis, Roche, Sanofi/Regeneron, TEVA, and Zambon.
Funding Information:
LGH has received institutional grant support from Aerocrine, Amgen, AstraZeneca, Genentech/Hoffman-La Roche, GlaxoSmithKline, Medimmune, Novartis UK, and Vitalograph. He has also received speaker's honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Napp Pharmaceuticals, and personal fees from AstraZeneca, Circassia, Evelo Biosciences, GlaxoSmithKline, Hoffman-la-Roche/Genentech Inc, Novartis, Sanofi, Teva, and Theravance; all outside of the published work.
Funding Information:
PGG has received speaker's honoraria from AstraZeneca, GlaxoSmithKline and Novartis and grant support from AstraZeneca and GlaxoSmithKline.
Funding Information:
HI has participated in Advisory boards and has received speaker's honoraria from Astellas, AstraZeneca, Boehringer Ingelheim, Chugai, GlaxoSmithKline, Kyorin, Merck Sharp & Dohme, Novartis, and Sanofi. He has also received research/educational grant support from Boehringer Ingelheim, Chugai, GlaxoSmithKline, Kyorin, Merck Sharp & Dohme, Novartis, Ono, Pfizer, Sanofi, Shionogi, Taiho, and Teijin-Pharma.
Funding Information:
VMMcD has received grant support from AstraZeneca and GlaxoSmithKline, and personal fees from AstraZeneca, GlaxoSmithKline, and Novartis; outside of the published work.
Funding Information:
IDP has received grant support from Chiesi, support from Regeneron and Sanofi, and non-financial support from Excerpta Medica, during the conduct of the study. He has also received grant support from Chiesi and support outside of the published work from Aerocrine AB, Almirall, AstraZeneca, Boehringer Ingelheim, Circassia, Dey Pharma, Genentech, GlaxoSmithKline, Knopp Biosciences, Merck, Merck Sharp & Dohme, Napp Pharmaceuticals, Novartis, Regeneron, RespiVert, Sanofi, Schering-Plough, and Teva.
Funding Information:
FJM reports support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Raziel Therapeutics during the conduct of the study. Outside of the published work, FJM reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Patara Pharma, ProterrixBio, Sanofi/Regeneron and Teva, and other/non-financial support from AbbVie, Afferent/Merck, Biogen, Bridge Biotherapeutics, and Gilead. He also reports grants from NIH, Canadian Respiratory Network, and ProMedior/Roche.
Publisher Copyright:
© 2021
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
Keywords:
Asthma, Biomarkers, COPD, Targeted therapy
Identifiers
Local EPrints ID: 452967
URI: http://eprints.soton.ac.uk/id/eprint/452967
ISSN: 0954-6111
PURE UUID: 74eca6eb-4d0b-4116-b973-8a5721132b52
Catalogue record
Date deposited: 07 Jan 2022 11:59
Last modified: 11 Jul 2024 04:53
Export record
Altmetrics
